Lijun International (01355.HK) Draws Market Attention with Synthetic Biology Transformation

1. Stock and Event Background
   :
   Lijun International (stock code: 01355.HK) is a Hong Kong Stock Exchange-listed company proposing to rename itself “Biosystem Engineering Limited” / Biosysen Limited, planning to transform into the synthetic biology field [1][2][3]. On December 30, 2025, the company was labeled a “HK Hot Stock”, with core drivers being its asset acquisition and business transformation plan announced on December 23.

2. Catalysts for Popularity
   :
   • Asset Acquisition
     : The company proposes to acquire 100% equity of Aonuo Hong Kong for HK$22 million, indirectly obtaining a 37.5% stake in Biosysen Biotech. Biosysen Biotech is a synthetic biology infrastructure supplier with closed-loop R&D and production capabilities [2][3].
   • Business Transformation and Renaming
     : To align with the synthetic biology business direction, the company proposes a name change to clarify its strategic focus [1][2].
     As a high-growth cutting-edge field, synthetic biology-related layouts usually attract market attention, which is the main reason for the stock’s popularity.

3. Price and Trading Volume Status
   :
   Due to data tool limitations, complete price trends and trading volume data from December 23 to 30, 2025 cannot be obtained. Limited information shows that the closing price on December 23 was HK$0.120, flat with the previous closing price, and the trading volume that day was 0 shares, indicating extremely inactive trading [1].

1. Track Linkage Effect
   : Market enthusiasm in the synthetic biology field has spread to related targets, and Lijun International’s transformation plan exactly aligns with investors’ attention boom in this field.
2. Clear Strategic Signal
   : The proposed renaming shows the company’s determination to transform into synthetic biology and intends to reshape market perception.
3. Data Transparency Challenge
   : The lack of key operational and financial information increases the difficulty for investors to evaluate the company’s value.
4. Segment Layout
   : Acquiring a stake in Biosysen Biotech to enter the synthetic biology infrastructure segment, which is a core support for industry development and has long-term value potential.

• Opportunities
  :
  • Synthetic biology, as an emerging track, has high growth potential; successful transformation is expected to enhance the company’s valuation space.
• Risks
  :
  • Data Missing Risk
    : Insufficient recent price, trading volume, and financial data, leading to lack of basic support for investment decisions.
  • Transformation Uncertainty
    : There are uncertainties in technology integration, market competitiveness, and profit prospects when transforming from the original business to synthetic biology.
  • Acquisition Risk
    : The actual operating status and technical strength of Biosysen Biotech are not public, so the acquisition value needs to be verified.
  • Liquidity Risk
    : Historically extremely low trading volume may lead to transaction difficulties and price manipulation risks.
  • Information Transparency Risk
    : Limited public information from the company makes it difficult for investors to conduct a comprehensive evaluation.

Lijun International (01355.HK) has become a Hong Kong stock hot pick due to its transformation into the synthetic biology field, with core catalysts being the asset acquisition and proposed renaming plan. The high growth potential of the synthetic biology track provides development opportunities for the company, but there are also risks such as data missing, transformation uncertainty, and information transparency. Due to recent price and trading volume data limitations, investors need to closely monitor the company’s transformation progress, acquisition completion status, and public information disclosure to obtain more sufficient decision-making basis.